http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110075121-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7088 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K33-243 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 |
| filingDate | 2019-05-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2022-01-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2022-01-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-110075121-B |
| titleOfInvention | Application of miR-4295 in preparation of medicine for treating gastric cancer |
| abstract | The invention belongs to the technical field of medicines, and relates to application of miR-4295 in preparation of a medicine for treating gastric cancer. miR-4295 targets and negatively regulates LRIG1 expression to activate EGFR/PI3K/AKT signaling pathway, thereby promoting proliferation of gastric cancer cells and inhibiting DDP-induced apoptosis of gastric cancer cells. Therefore, miR-4295 is a novel therapeutic target for gastric cancer patients. |
| priorityDate | 2018-07-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 142.